Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.

Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.

2.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

4.
5.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

6.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

7.
8.
9.
10.

Treating hepatitis C in the prison population is cost-saving.

Tan JA, Joseph TA, Saab S.

Hepatology. 2008 Nov;48(5):1387-95. doi: 10.1002/hep.22509. Review.

PMID:
18924228
11.

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

Sagmeister M, Wong JB, Mullhaupt B, Renner EL.

Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8. Review.

PMID:
11396525
12.

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.

Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O'Brien J, Thalassinos E, Papastergiou V, Burroughs A.

Health Technol Assess. 2015 Jan;19(9):1-409, v-vi. doi: 10.3310/hta19090. Review.

14.

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin HF, Cave CB, Waugh NR, Price A, Gabbay J.

Int J Technol Assess Health Care. 2005 Winter;21(1):47-54. Review.

PMID:
15736514
15.

Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.

John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M.

Pharmacoeconomics. 2012 Nov 1;30(11):1015-34. doi: 10.2165/11597660-000000000-00000. Review.

PMID:
23050771
16.

Economic evaluation of HCV testing approaches in low and middle income countries.

Morgan JR, Servidone M, Easterbrook P, Linas BP.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):697. doi: 10.1186/s12879-017-2779-9. Review.

17.

Economic Burden of Hepatitis C Infection.

Stepanova M, Younossi ZM.

Clin Liver Dis. 2017 Aug;21(3):579-594. doi: 10.1016/j.cld.2017.03.012. Epub 2017 Apr 22. Review.

PMID:
28689595

Supplemental Content

Support Center